| Line Item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | |||||||||
| Research and Development | |||||||||
| Operating expenses | |||||||||
| Total operating expenses | |||||||||
| Loss from operations | |||||||||
| Finance and Other income/(expense): | |||||||||
| Finance income | |||||||||
| FV Gain/(Loss) on Investment | |||||||||
| Gain/on sale of Investment | |||||||||
| Total other income/(expense) | |||||||||
| Loss from operations before income taxes | |||||||||
| Income tax credit/(expense) | — | ||||||||
| Loss for the year | |||||||||
| Other Comprehensive loss: | |||||||||
| Gain/(Loss) on currency translation | |||||||||
| Comprehensive loss | |||||||||
| Basic loss per share attributable to common shareholders (in Dollars per share) | |||||||||
| Diluted loss per share attributable to common shareholders (in Dollars per share) |